Bamco Inc. NY Buys Shares of 12,500 Revolution Medicines, Inc. $RVMD

Bamco Inc. NY bought a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 12,500 shares of the company's stock, valued at approximately $2,341,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in RVMD. Alphabet Inc. acquired a new position in Revolution Medicines in the 2nd quarter worth about $551,843,000. Norges Bank bought a new stake in shares of Revolution Medicines during the fourth quarter worth about $195,568,000. Avoro Capital Advisors LLC bought a new stake in shares of Revolution Medicines during the fourth quarter worth about $172,840,000. Polar Capital Holdings Plc increased its stake in shares of Revolution Medicines by 321.2% in the fourth quarter. Polar Capital Holdings Plc now owns 2,013,791 shares of the company's stock valued at $160,398,000 after buying an additional 1,535,686 shares during the period. Finally, Adage Capital Partners GP L.L.C. increased its stake in shares of Revolution Medicines by 197.1% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 2,205,555 shares of the company's stock valued at $175,672,000 after buying an additional 1,463,155 shares during the period. Institutional investors own 94.34% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on RVMD shares. Wedbush boosted their target price on shares of Revolution Medicines from $201.00 to $225.00 and gave the stock an "outperform" rating in a report on Thursday. Raymond James Financial reaffirmed a "strong-buy" rating and set a $248.00 price target on shares of Revolution Medicines in a research note on Thursday. Oppenheimer lifted their price target on shares of Revolution Medicines from $230.00 to $260.00 and gave the stock an "outperform" rating in a report on Thursday. Wolfe Research reissued an "outperform" rating and issued a $220.00 price objective on shares of Revolution Medicines in a research note on Monday, August 10th. Finally, Truist Financial increased their price objective on Revolution Medicines from $231.00 to $239.00 and gave the company a "buy" rating in a report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Revolution Medicines presently has an average rating of "Moderate Buy" and a consensus price target of $193.28.

Revolution Medicines Stock Up 2.7%

Shares of NASDAQ:RVMD opened at $221.15 on Friday. Revolution Medicines, Inc. has a 1 year low of $37.56 and a 1 year high of $224.31. The company has a debt-to-equity ratio of 0.40, a current ratio of 11.38 and a quick ratio of 11.38. The business's 50-day moving average is $192.43 and its 200-day moving average is $148.17. The company has a market capitalization of $47.40 billion, a price-to-earnings ratio of -25.07 and a beta of 1.39.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same quarter in the previous year, the company earned ($1.31) EPS. Equities research analysts predict that Revolution Medicines, Inc. will post -8.82 earnings per share for the current year.

Insiders Place Their Bets

In other Revolution Medicines news, CFO Jack Anders sold 20,000 shares of the firm's stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $168.33, for a total value of $3,366,600.00. Following the transaction, the chief financial officer directly owned 123,269 shares of the company's stock, valued at approximately $20,749,870.77. This trade represents a 13.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Sushil Patel sold 5,580 shares of the business's stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $187.99, for a total transaction of $1,048,984.20. Following the sale, the director directly owned 21,656 shares of the company's stock, valued at approximately $4,071,111.44. The trade was a 20.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 212,497 shares of company stock valued at $38,206,486. 7.60% of the stock is currently owned by corporate insiders.

Key Stories Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Landmark FDA approval: RASONQUE is described as the first broad RAS-targeted medicine approved for metastatic pancreatic cancer, addressing a disease with limited treatment options and potentially validating Revolution Medicines’ RAS/MAPK drug-development platform. FDA approval announcement
• Positive Sentiment: Commercial opportunity expands: Analysts said the RASONQUE label creates a sizable opportunity, while RBC viewed the company’s planned launch as rapid. Management’s discussion also emphasized the approval’s implications for broader RAS-driven cancer treatment and future indications. Rasonque label expansion analysis
• Positive Sentiment: Higher analyst targets: Truist raised its price target from $231 to $239 and maintained a Buy rating, while Wedbush increased its target from $201 to $225 and kept an Outperform rating. These revisions reflect improved confidence following the approval. Analyst price target changes
• Neutral Sentiment: Pricing and launch execution will matter: Revolution Medicines priced RASONQUE at approximately $39,800 per month. The price supports substantial revenue potential, but payer coverage, patient access and real-world adoption could influence how quickly the approval translates into sales. Rasonque pricing article
• Negative Sentiment: Insider selling and ongoing losses remain risks: Insider Mark Goldsmith sold 80,000 shares for roughly $16.7 million, reducing his holdings by about 23%. Revolution Medicines also remains unprofitable, and its latest quarterly loss exceeded analyst expectations, so the stock’s valuation depends heavily on successful commercialization and pipeline progress. Insider sale report

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source